The PennZone

  • Home
  • Business
  • Health
  • Technology
  • Non-profit
  • Financial
  • Services
  • Entertainment
  • Construction

SafER has announced a Stage 3 clinical trial evaluating the SafER Negative Pressure System reducing aerosol emissions during bronchoscopic procedures
The PennZone/10271927

Trending...
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • CCHR: New Data Shows Millions of U.S. Children Caught in Escalating Psychiatric Polypharmacy
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
Vacuum And Mask Respiratory Shield Endo Shield Hospital Nosuction 1 Hospital Suction 1c SafER Medical Products LLC
BRANSON, Mo. - PennZone -- Bronchoscopy is known to be an aerosol generating procedure and produce plumes of microscopic particles, some of which may carry infectious airborne organisms, that can then be inhaled by medical personnel in attendance and subsequently pose a high-risk of those medical staff contracting the disease.  "Our goal since the beginning of the pandemic has been to create a safer work environment for our friends and colleagues who are exposed to dangerous pathogens when performing aerosol generating procedures, while expanding access to those life-saving procedures for our patients", said SafER Chief Medical Officer, Dr. Rick Blubaugh.

The SafER system is the world's first portable negative pressure system that utilizes HEPA filtration to capture dangerous fugitive emissions at the source – the patient.  The system has been in use since the pandemic in hospitals, ambulances, and long-term facilities around the country and can be utilized during a variety of procedures including intubation, nebulizer, CPAP or Bi-Level PAP, endoscopy, and sputum or swab collection.

More on The PennZone
  • UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
  • 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
  • Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
  • From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
  • Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."

The study is randomized controlled and will take place in a 1,000-bed tertiary facility and is expected to enroll 80 patients over a 3-month period.  The goals of the study are to assess the system and the reduction of aerosol emissions produced during bronchoscopic procedures.  Results of the study are expected to be announced late this summer.

http://www.safermedicalproducts.com

Contact
Carl Baker
cbaker@safermedicalproducts.com


Source: SafER Medical Products LLC
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
  • New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
  • BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
  • FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
  • African American Genealogy Group Launches 2025 Raffle Fundraiser to Support Legacy Research
  • Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
  • Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
  • LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
  • Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
  • Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
  • Ring in the Season with Free Holiday Jazz from The Jazz Sanctuary
  • America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 421
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 186
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • BITE Data raises $3m to build AI tools for global trade compliance teams
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
  • CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf

Similar on PennZone

  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
  • Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
  • Signature Smiles Dental Group Unveils New User-Friendly Website
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us